Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-85.54%
operating margin TTM
-79.63%
revenue TTM
517.28 Million
revenue per share TTM
5.35$
valuation ratios | |
|---|---|
| pe ratio | -3.98 |
| peg ratio | -2.36 |
| price to book ratio | -28.60 |
| price to sales ratio | 3.29 |
| enterprise value multiple | -2.86 |
| price fair value | -28.60 |
profitability ratios | |
|---|---|
| gross profit margin | 83.85% |
| operating profit margin | -79.63% |
| pretax profit margin | -84.93% |
| net profit margin | -85.54% |
| return on assets | -37.56% |
| return on equity | -1024.42% |
| return on capital employed | -46.67% |
liquidity ratios | |
|---|---|
| current ratio | 2.48 |
| quick ratio | 2.34 |
| cash ratio | 1.13 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 174.68 |
| operating cycle | 260.95 |
| days of payables outstanding | 104.14 |
| cash conversion cycle | 156.81 |
| receivables turnover | 4.23 |
| payables turnover | 3.51 |
| inventory turnover | 2.09 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.83 |
| debt equity ratio | -15.95 |
| long term debt to capitalization | 1.07 |
| total debt to capitalization | 1.07 |
| interest coverage | -8.71 |
| cash flow to debt ratio | -0.37 |
cash flow ratios | |
|---|---|
| free cash flow per share | -4.72 |
| cash per share | 6.94 |
| operating cash flow per share | -4.66 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -0.37 |
| short term coverage ratios | -5.75 |
| capital expenditure coverage ratio | -77.67 |
Frequently Asked Questions
When was the last time Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported earnings?
Ultragenyx Pharmaceutical Inc. (RARE) published its most recent earnings results on 05-11-2025.
What is Ultragenyx Pharmaceutical Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)'s trailing twelve months ROE is -1024.42%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Ultragenyx Pharmaceutical Inc. (RARE) currently has a ROA of -37.56%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did RARE's net profit margin stand at?
RARE reported a profit margin of -85.54% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is RARE's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.48 in the most recent quarter. The quick ratio stood at 2.34, with a Debt/Eq ratio of -15.95.